BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2021947)

  • 1. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate.
    LeBerthon B; Khawli LA; Alauddin M; Miller GK; Charak BS; Mazumder A; Epstein AL
    Cancer Res; 1991 May; 51(10):2694-8. PubMed ID: 2021947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
    Epstein AL; Khawli LA; Hornick JL; Taylor CR
    Cancer Res; 1995 Jun; 55(12):2673-80. PubMed ID: 7780984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.
    Hornick JL; Khawli LA; Hu P; Sharifi J; Khanna C; Epstein AL
    Clin Cancer Res; 1999 Jan; 5(1):51-60. PubMed ID: 9918202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake.
    Hu P; Hornick JL; Glasky MS; Yun A; Milkie MN; Khawli LA; Anderson PM; Epstein AL
    Cancer Res; 1996 Nov; 56(21):4998-5004. PubMed ID: 8895756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
    Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I; Agah R; Hu E; Mazumder A
    Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels.
    Shockley TR; Lin K; Sung C; Nagy JA; Tompkins RG; Dedrick RL; Dvorak HF; Yarmush ML
    Cancer Res; 1992 Jan; 52(2):357-66. PubMed ID: 1728407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts.
    Lin K; Nagy JA; Xu H; Shockley TR; Yarmush ML; Dvorak HF
    Cancer Res; 1994 Apr; 54(8):2269-77. PubMed ID: 8174137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens.
    Sharkey RM; Gold DV; Aninipot R; Vagg R; Ballance C; Newman ES; Ostella F; Hansen HJ; Goldenberg DM
    Cancer Res; 1990 Feb; 50(3 Suppl):828s-834s. PubMed ID: 2297729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.
    Sung C; Shockley TR; Morrison PF; Dvorak HF; Yarmush ML; Dedrick RL
    Cancer Res; 1992 Jan; 52(2):377-84. PubMed ID: 1728409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts.
    Shockley TR; Lin K; Nagy JA; Tompkins RG; Yarmush ML; Dvorak HF
    Cancer Res; 1992 Jan; 52(2):367-76. PubMed ID: 1728408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution of iodine-125 labeled monoclonal antibody/interleukin-2 immunoconjugate in athymic mice bearing human tumor xenografts.
    Nakamura K; Kubo A
    Cancer; 1997 Dec; 80(12 Suppl):2650-5. PubMed ID: 9406720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E; Sein JJ; van den Berk PC; Hart AA; van der Valk MA; Kast WM; Melief CJ; Hekman A
    Cancer Res; 1995 Jun; 55(12):2627-34. PubMed ID: 7540106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
    Stastny JJ; Das Gupta TK
    Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.